Genetics
IL-6 receptor signalling and Lp(a) independently lower cardiovascular risk, Mendelian randomisation study (JACC Basic Transl Sci 2026)
Original title: Mendelian Randomization Reveals Interleukin-6 Receptor-Lipoprotein(a) Interplay With Independent Cardiovascular Risk Reductions
Two-sample Mendelian randomisation study supporting a causal effect of interleukin-6 receptor (IL-6R) signalling on Lp(a) concentrations, revealing a direct interplay between two independent causal cardiovascular risk factors. UK Biobank epidemiological analyses showed that neglecting IL-6R functional state can confound the apparent association between circulating IL-6 and Lp(a), though the effect of IL-6 on Lp(a) remained modest even after accounting for receptor function. Factorial Mendelian randomisation indicated that down-regulating IL-6R signalling and lowering Lp(a) each independently reduce cardiovascular disease risk, without redundancy between the two pathways. The authors highlight this as offering complementary opportunities for cardiovascular risk mitigation via two distinct, druggable pathways.
Original abstract
In the study at hand, 2-sample Mendelian randomization supported a causal effect of interleukin-6 receptor (IL-6R) signaling on Lp(a) concentrations, revealing a direct interplay between 2 causal risk factors for cardiovascular disease (CVD). Importantly, epidemiological analyses in UK Biobank showed that neglecting the IL-6R functional state can confound the association between IL-6 levels and Lp(a). However, the effect of circulating IL-6 on Lp(a) concentrations was modest even when the functional state of the receptor was considered. In line, factorial Mendelian randomization indicated that down-regulation of IL-6R signaling and Lp(a) independently reduce CVD risk, highlighting complementary opportunities for CVD risk mitigation.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.